Pharma Industry News

Novartis’ Zolgensma shows ‘continued benefit’ in SMA patients

66.7% of patients in the intent-to-treat population were able to feed orally without the need for feeding supportOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]